Palatin Applied sciences’ Weight problems Drug Co-Administered With Eli Lilly’s Blockbuster Drug Exhibits 4.4% Discount In Weight – Palatin Techs (AMEX:PTN)

Palatin Applied sciences Inc. PTN on Monday reported topline knowledge with co-administered melanocortin-4 receptor (MC4R) agonist bremelanotide plus glucagon-like peptide-1/gastric inhibitory polypeptide (GLP-1/GIP) tirzepatide.

Eli Lilly And Co’s LLY tirzepatide is offered as Mounjaro and Zepbound for diabetes and weight reduction.

Topline knowledge outcomes from the research have been extremely statistically important for the research’s major endpoint, which was % weight reduction in sufferers for the co-administration of MC4R agonist bremelanotide plus GLP-1/GLP tirzepatide in comparison with placebo, over the 8-week remedy interval.

• The co-administered group had a 4.4% discount in weight in comparison with 1.6% for the placebo group.

Additionally Learn: Palatin Applied sciences Touts Constructive Outcomes From Mid-Stage Examine For Experimental Drug For Ulcerative Colitis, Halts Sufferers Enrollment Citing Strategic Focus

The first evaluation for additive impact demonstrated that:

• 40% of sufferers within the co-administered group achieved a 5% discount of their physique weight, in comparison with 27% for the tirzepatide alone group.
• 27% of sufferers within the co-administered group achieved a 6% discount of their physique weight, in comparison with 13% for the tirzepatide alone group.
• 19% of sufferers within the co-administered group achieved a 7% discount of their physique weight, in comparison with 0% for the tirzepatide alone group.

Over 50% of the misplaced weight was regained inside two weeks after remedy cessation in each the co-administration and the tirzepatide-only teams, a typical prevalence following the discontinuation of GLP-1/GIP remedy.

The info indicated that weight regain was successfully halted within the MC4R agonist bremelanotide group.

Moreover, co-administration of the MC4R agonist with the GLP-1/GIP remedy confirmed no improve in security or tolerability considerations amongst sufferers.

Additional knowledge evaluation is ongoing, together with exploratory endpoints akin to physique composition and physique mass index.

Palatin is advancing the event of its next-generation MC4R long-acting peptide and oral small molecule compounds as stand-alone remedies, in addition to together with GLP-1/GIP (incretin remedy), and as monotherapy for a number of genetic weight problems problems.

Investigational New Drug functions are anticipated to be submitted within the fourth quarter of calendar 2025, with medical knowledge anticipated within the first half of 2026.

Worth Motion: PTN inventory is down 14.6% at $0.5656 on the final examine Monday.

Learn Subsequent:

Picture through Shutterstock.